Size Doesn't Matter: US FDA Refines Dig-Health Pre-Cert Model
Executive Summary
After receiving feedback from industry and other stakeholders, FDA has revised its "working model" for its planned pre-certification program for health software. It now states that size of a company will not preclude them from participating in the program. The agency has also refined how it will conduct appraisals.
You may also be interested in...
US Senators Question FDA's Pre-Cert Program Authority, Concerned About Safety
Top Democratic lawmakers on the Senate HELP Committee have written to US FDA Commissioner Scott Gottlieb with questions about the agency's ongoing work to develop a pre-certification program that would allow medical software-makers to gain the agency's trust as a means to benefit from reduced or no pre-market review.
FDA: Apple De Novo Approvals Signal Innovation To Digital Health Firms
The latest Apple Watch includes an electrocardiogram that has received de novo clearance from US FDA to detect irregular heart rhythms. The approval, say two top US FDA regulators, is a signal to the digital health industry that the agency is trying to help them innovate.
US FDA's Software Pre-Cert Program: Is The Authority On The Books?
The agency is building its pre-certification program as a novel paradigm for health software products to reach the market with less scrutiny when companies successfully undergo "excellence" appraisals. It has attracted the interest and support of many stakeholders, but at least one medtech group argues the agency should have to get congressional approval to launch the program.